Meta-analysis and investigation of anti-infective therapies

Bibliography

• DICKERSIN K, BERLIN JA: Meta-analysis: state of the science. Epidemiol. Rev. (1992) 14:154–176.
   PubMed Web of Science ®Google Scholar
• BULPITT J: Meta-analysis. Lancet (1988) 2:93–94.
   PubMed Web of Science ®Google Scholar
• COLLINS R, PETO R, GRAY R, PARISH S: Large scale randomised evidence: trials and overviews. In: Oxford Textbook of Medicine (Third Edition). Weatherall DJ, Leding-ham JGG, Warren DA (Eds.), Oxford Medical Publications, Oxford (1996):21–32.
   Google Scholar
• CUMMINGS P: Antibiotics to prevent infection in pa-tients with dog bite wounds: a meta-analysis o f random-ised trials. Ann. Emerg. Med. (1994) 23:535–540.
   PubMed Web of Science ®Google Scholar
• JERNIGAN JA, FARR BM: Short-course therapy of catheter related Staphylococcus aureus bacteraemia: a meta-analysis. Ann. Intern. Med. (1993) 119:304–311.
   PubMed Web of Science ®Google Scholar
• SANDERS JW, POVVE NR, MOORE RD: Ceftazidime mono-therapy for empiric treatment of febrile neutropaenic patients: a meta-analysis. J. Infect Dis. (1991) 164:907–916.
   PubMed Web of Science ®Google Scholar
• WILLIAMS RL, CHALMERS TC, STANGE KC, CHALMERS FT, BOWLIN SJ: Use of antibiotics in preventing recurrent otitis media and in treating otitis media with effusion: a meta-analytic attempt to resolve the brouhaha. JAMA (1993) 270:1344–1351.
   PubMed Web of Science ®Google Scholar
• ROVERS JP, ILERSICH AL, EINARSON TR: Meta-analysis of par enteral clindamycin dosing regimens. Ann. Pharma-cother. (1995) 29:852–858.
   PubMedGoogle Scholar
• HENRY D, LIM L-Y, GARCIA-RODRIGUEZ LAG, et al: Vari-ability in gastr ointe stinal complications with incividual non-steroidal anti-inflammatory drugs: results of a col-laborative meta-analysis. Br. Med. J. (1996) 312:1563–1566.
   PubMed Web of Science ®Google Scholar
• HURLEY JC: Concordance of endotoxaemia with Gram-negative bacteraemia in patients with Gram-negative sepsis: a meta-analysis. J. Gin. Microbiol (1994) 32:2120–2127.
   Google Scholar
• VANDENBROUCKE-GRAULS CMJE, VANDERBROUCKE JP:Effect of selective decontamination of the digestive tract on respiratory tract infections and mortality in the intensive care unit. Lancet (1991) 338:859–862.
   PubMed Web of Science ®Google Scholar
• SELECTIVE DECONTAMINATION OF THE DIGESTIVE TRACT TRIALIST'S COLLABORATIVE GROUP: Meta-analy-sis of randomised controlled trials of selective decon-tamination of the digestive tract. Br. Med. J. (1993) 307:525–532.
   PubMedGoogle Scholar
• KOLLEF, MH: The role of selective digestive tract decon-tamination on mortality and respiratory tract infec-tions: a meta-analysis. Chest (1994) 105:1101–1108.
   PubMed Web of Science ®Google Scholar
• HURLEY JC: Prophylaxis with enteral antibiotics in ventilated patients: selective decontamination or selec-tive cross infection? Antimicrob. Agents Chemother. (1995) 39:941–947.
   PubMed Web of Science ®Google Scholar
• LEFERING R, NEUGEBAUER EAM: Steroid controversy in sepsis and septic shock. A meta-analysis. Crit Care Med. (1995) 23:1294–1303.
   PubMed Web of Science ®Google Scholar
• CRONIN L, COOK DJ, CARLET J et al: Corticosteroid treatment for sepsis: a critical appraisal and meta-analy-sis of the literature. Crit Care Med. (1995) 23:1430–1439.
   PubMed Web of Science ®Google Scholar
• BLASER J, KONIG C: Once daily dosing of aminogly-cosides. Eur.j Clin. Microbiol Infect. Dis. (1995) 14:1029–1038.
   PubMed Web of Science ®Google Scholar
• •How not to do a meta-analysis.
   Google Scholar
• BARZA M, IOANNIDIS PA, CAPPELLERI JC, LAU J: Single or multiple daily doses of aminoglycosides: a meta-analy-sis. Br. Med. J (1996) 312:338-345. Example of a sophisticated meta-analysis.
   Google Scholar
• HATALA R, DINH T, COOK D: Once daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann. Int Med. (1996) 124(8):717–725.
   PubMed Web of Science ®Google Scholar
• MUNCKHOF WJ, GRAYSON ML, TURNIDGE JD: A meta-analysis of studies on the safety and efficacy of amino-glycosides given as once daily or as divided doses. J. Antimicrob. Chemoher. (1996) 37:645–663.
   PubMed Web of Science ®Google Scholar
• THOMPSON SG: Why sources of heterogeneity in meta-analysis should be investigated. Br. Med. J. (1994) 309:1351-1355. Illustrates by example how a summary result may mislead.
   Google Scholar
• DERSIMONIAN R, LAIRD N: Meta-analysis in clinical tri-als. Control. Clin. Trials (1986) 7:177–188.
   PubMedGoogle Scholar
• MANTEL N, HAENSZEL W: Statistical aspects of the analy-sis of data from retrospective studies of disease. J. Natl. Cancer Inst (1959) 22:719–748.
   PubMed Web of Science ®Google Scholar
• NICOLAU DP, FREEMAN CD, BELLIVAU PB et al: Experi-ence with once daily aminoglycoside program admin-istered to 2184 adult patients. Antimicrob. Agent Chemother. (1995) 39:650–655.
   PubMed Web of Science ®Google Scholar
• DUFFULL SB, BEGG EJ, CHAMBERS ST, BARCLAY ML: Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with a dy-namic in vitro model. Antimicrob. Agents Chemother. (1994) 38:2480–2482.
   PubMed Web of Science ®Google Scholar
• BEGG EJ, PEDDIE BA, CHAMBERS ST, BOSWELL DR: Com-parison of gentamicin dosing regimens using an in vitro model. J. Antimicrob. Chemother. (1992) 29:427–433.
   PubMed Web of Science ®Google Scholar
• BARMADA S, KOHLHEPP S, LEGGETT J. DWORKIN R, GILBERT D: Correlation of tobramycin induced inhibi-tion of protein synthesis with postantibiotic effect in Escherichia coli Antimicrob. Agents Chemother. (1993) 37:2678–2683.
   Google Scholar
• MCGRATH BJ, MARCHBANKS C, GILBERT D, DUDLEY MN: In vitro post antibiotic effect following repeated expo-sure to imipenem, temafloxacin, and tobramycin. An-timicrob. Aunts Chemother. (1993) 37:1723–1725.
   PubMed Web of Science ®Google Scholar
• GAVALDA J, PAHISSA A, ALIMRARTE B et al.: Effect of gentamicin dosing interval on therapy of viridans st re-tococcal experimental endocarditis with gentamicin plus penicillin. Antimicrob. Agents Chemother. (1995) 39:2098–2103.
   PubMed Web of Science ®Google Scholar
• FANTIN B, CARBON C: Importance of the aminogly-coside dosing regimen in the penicillin-netilmycin combination for treatment of Enterococcus faecalis induced experimental endocarditis. Antimicrob. Agent Chemother. (1990) 34:2387–2391.
   PubMed Web of Science ®Google Scholar
• SUN X, WAGNER DP, KNAUS WA: Does selective decon-tamination of the digestive tract reduce mortality for severely ill patients. Grit. Care Med. (1996) 24:753–755.
   PubMed Web of Science ®Google Scholar
• SHARP SJ, THOMPSON SG, ALTMAN DG: The relationship between treatment benefit and underlying risk in meta-analysis. Br. Med. J. (1996) 313:735–738.
   PubMed Web of Science ®Google Scholar
• QUINIO B, ALBANESE J, BUES-CHARBIT M, VIVIAND X, MARTIN C: Selective decontamination of the digestive tract in multiple trauma patients. A prospective double-blind randomised placebo-controlled study. Chest (1996) 109:765–772.
   Google Scholar
• BORZAK S, RIDKER PM: Discordance between meta-analyses and large scale randomised clinical trials. Examples from the management of acute myocardial infarction. Ann. Intern. Med (1995) 123:873–877.
   Google Scholar
• YUSUF S, COLLINS R, PETO R et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, rein-farction and side-effects from 33 randomised control-led trials. Eur Heart J. (1985) 6:566–585
   Google Scholar
• GRUPPO ITALIANO PER LO STUDIO DELLA STREPTOCHI-NASI NELLINFARTO MIOCARDICO (GISSI): Effectiveness of intravenous thrombolytic treatment in acute myo-cardial infarction. Lancet (1986) 1:397–402.
   PubMed Web of Science ®Google Scholar
• YUSUF S. PETO R, LEWIS J, COLLINS R, SLEIGHT P: Beta-blockade during and after myocardial infarction: an overview of the randomised trials. Prog Cardiovasc Dis. (1985) 27:335–373
   PubMed Web of Science ®Google Scholar
• ISIS-1 (FIRST INTERNATIONAL STUDY OF INFARCT SUR-VIVAL) COLLABORATIVE GROUP: Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction:ISIS-1. Lancet. (1986) 2:57–
   PubMed Web of Science ®Google Scholar
• YUSUF S, COLLINS R, MACMAHON S, PETO R: Effect ofintravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet (1988) 1:1088–1092.
   PubMed Web of Science ®Google Scholar
• GRUPPO ITALIANO PER LO STUDIO DELLA SOPRAV-VIVENZA NELLINFARTO MIOCARDICO (GISSI-3): Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular func-tion after acute myocardial infarction. Lancet (1994) 343:1115–1122
   PubMed Web of Science ®Google Scholar
• ISIS-4 (FOURTH INTERNATIONAL STUDY OF INFARCT SURVIVAL) COLLABORATIVE GROUP: A randomised fac-torial trial assessing early oral captopril, oral mononi-trate, and intravenous magnesium sulphate on 58,050 patients with suspected acute myocardial infarction. ISIS-4. Lancet (1995) 345:669–685
   Google Scholar
• WOODS KL, FLETCHER S, ROFFE C, HAIDER Y: Intrave-nous magnesium sulphate in suspected acute myocar-dial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet (1992) 339:1553–1558
   PubMed Web of Science ®Google Scholar
• RAVNSKOV U: Cholesterol lowering trials in coronary artery disease: frequency of citation and outcome. Br. Med. J. (1992) 305:15–19.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J, COBBE SM, FORD I et aL: FOR THE WEST OF SCOTLAND CORONARY PREVENTION STUDY GROUP: Prevention of coronary heart disease in men with hyper cholesterolemia . New Engl. J. Med. (1995) 333:1301–1307.
   PubMed Web of Science ®Google Scholar
• THE SCANDINAVIAN SIMVASTATIN STUDY GROUP: Ran-domised study of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvas-tatin Survival Study (4S). Lancet (1994) 344:1383-1389. James Hurley
   Google Scholar